Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Creative Medical Technology Holdings (CELZ) Other Non Operating Income (2018 - 2020)

Creative Medical Technology Holdings has reported Other Non Operating Income over the past 3 years, most recently at -$38.0 million for Q4 2020.

  • Quarterly Other Non Operating Income fell 13118.37% to -$38.0 million in Q4 2020 from the year-ago period, while the trailing twelve-month figure was -$38.0 million through Mar 2021, down 12649.59% year-over-year, with the annual reading at -$34.0 million for FY2020, 9183.31% down from the prior year.
  • Other Non Operating Income was -$38.0 million for Q4 2020 at Creative Medical Technology Holdings, down from $291723.0 in the prior quarter.
  • Over five years, Other Non Operating Income peaked at $650929.0 in Q2 2018 and troughed at -$38.0 million in Q4 2020.
  • The 3-year median for Other Non Operating Income is -$88244.0 (2018), against an average of -$5.4 million.
  • Biggest five-year swings in Other Non Operating Income: skyrocketed 430.59% in 2019 and later tumbled 13118.37% in 2020.
  • Tracing CELZ's Other Non Operating Income over 3 years: stood at -$88244.0 in 2018, then skyrocketed by 430.59% to $291723.0 in 2019, then tumbled by 13118.37% to -$38.0 million in 2020.
  • According to Business Quant data, Other Non Operating Income over the past three periods came in at -$38.0 million, $291723.0, and $10897.0 for Q4 2020, Q4 2019, and Q3 2019 respectively.